Pfizer CentreOne, a contract manufacturing organization (CMO) within Pfizer, has expanded its fill-finish services at its Kalamazoo, Michigan site. The facility now provides vial-filling of sterile suspensions along with vial-filling of small molecules and biologics.
Pfizer CentreOne’s vial-filling services at the Kalamazoo site encompass small molecules and biologics, sterile suspensions, potent and controlled substances, aqueous and oil-based formulations, lyophilization, vials in 1-mL to 100-mL sizes, bulk formulation ranging from less than 1 liter to 1,600 liters, and technical transfer.
The CMO was formed by the union of Pfizer CentreSource and Hospira One 2 One, a sterile-injectables CMO, following Pfizer’s $17-billion acquisition of Hospira in 2015. Pfizer CentreOne focuses on active pharmaceutical ingredient synthesis, sterile injectables fill-finish, and highly potent solids.
Source: Pfizer CentreOne